Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2
W Holman, W Holman, S McIntosh, W Painter… - Trials, 2021 - Springer
A recently published article described the safety, tolerability, and pharmacokinetic profile of
molnupiravir (Painter et al. 2021), a novel antiviral agent with potent activity against severe …
molnupiravir (Painter et al. 2021), a novel antiviral agent with potent activity against severe …
Phase 2/3 trial of molnupiravir for treatment of Covid-19 in nonhospitalized adults
Y Caraco, GE Crofoot, PA Moncada… - NEJM …, 2022 - evidence.nejm.org
Background Safe and effective oral treatments are needed to improve clinical outcomes for
nonhospitalized patients with Covid-19. Molnupiravir is an orally administered, small …
nonhospitalized patients with Covid-19. Molnupiravir is an orally administered, small …
Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19
GR Painter, MG Natchus, O Cohen, W Holman… - Current opinion in …, 2021 - Elsevier
Highlights•Molnupiravir is a broad acting, oral antiviral versus SARS-CoV-2, flu, Ebola and
others.•Clinical development was greatly accelerated in response to the COVID19 …
others.•Clinical development was greatly accelerated in response to the COVID19 …
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
There is an urgent need for an effective, oral, direct-acting therapeutic to block transmission
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression …
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression …
Progress toward a large-scale synthesis of molnupiravir (MK-4482, EIDD-2801) from cytidine
GP Ahlqvist, CP McGeough, C Senanayake… - ACS …, 2021 - ACS Publications
Molnupiravir (MK-4482, EIDD-2801) is a promising orally bioavailable drug candidate for the
treatment of COVID-19. Herein, we describe a supply-centered and chromatography-free …
treatment of COVID-19. Herein, we describe a supply-centered and chromatography-free …
Molnupiravir: first approval
YY Syed - Drugs, 2022 - Springer
Molnupiravir (Lagevrio®) is an orally-administered antiviral prodrug that inhibits replication
of RNA viruses through viral error induction. It is being developed by Merck and Ridgeback …
of RNA viruses through viral error induction. It is being developed by Merck and Ridgeback …
Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2
WP Painter, W Holman, JA Bush… - Antimicrobial agents …, 2021 - Am Soc Microbiol
ABSTRACT Molnupiravir (EIDD-2801/MK-4482), the prodrug of the active antiviral
ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931), has activity against a …
ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931), has activity against a …
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled …
MG Johnson, JM Strizki, ML Brown, H Wan… - Infection, 2023 - Springer
Purpose Immunocompromised patients have a potentially increased risk for progression to
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …
Short Synthesis of Molnupiravir (EIDD-2801) via a Thionated Uridine Intermediate
Molnupiravir (MK-4482, EIDD-2801) is an experimental drug that has been demonstrated to
be effective for the treatment of COVID-19 in human clinical trials. Herein, we report a …
be effective for the treatment of COVID-19 in human clinical trials. Herein, we report a …
[HTML][HTML] Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model
DM Johnson, T Brasel, S Massey, T Garron, M Grimes… - Antiviral research, 2023 - Elsevier
Abstract Molnupiravir (EIDD-2801) is a prodrug of a ribonucleoside analogue that is
currently being used under a US FDA emergency use authorization for the treatment of mild …
currently being used under a US FDA emergency use authorization for the treatment of mild …